Introduction
Aging remains one of the most significant biological risk factors associated with neurodegenerative conditions. Across the lifespan, progressive molecular alterations—ranging from mitochondrial decline to chronic low-grade inflammation—create a cellular environment that favors degeneration and impaired repair capacity. Among these changes, the accumulation of senescent cells has gained increasing attention for its potential role in shaping the trajectory of age-related disorders. These cells, once beneficial in tissue maintenance and wound repair, may instead contribute to chronic inflammation and neurodegeneration when they accumulate within the central nervous system (CNS).
Recent preclinical investigations have begun to link cellular senescence to several hallmark pathologies associated with Alzheimer’s disease (AD), including amyloid-β (Aβ) accumulation, tau aggregation, and neuroinflammatory activation. Rather than merely being a byproduct of damage, senescent cells appear capable of actively driving pathological cascades through their secretory phenotype. Understanding the mechanisms through which senescent cells arise and persist in neural tissue may therefore provide valuable insight into how neurodegenerative processes initiate and progress.
Molecular Induction of Senescence in Neural Systems
Senescent cells are characterized by a stable, irreversible cell-cycle arrest triggered by various stressors such as DNA damage, oxidative imbalance, and protein misfolding. In neural tissue, accumulating evidence suggests that Aβ and tau—two key proteins involved in AD pathology—can induce this arrested state in glial and progenitor cells. These stimuli activate damage response pathways and upregulate signaling molecules such as p16^INK4a^ and p21, leading to a permanent halt in proliferation. The resulting senescent phenotype is often accompanied by resistance to apoptosis and an increase in the secretion of proinflammatory cytokines, chemokines, and proteases collectively referred to as the senescence-associated secretory phenotype (SASP).
This altered signaling environment appears to propagate dysfunction to nearby cells, amplifying neuroinflammatory conditions and impairing synaptic health.
Glial and Oligodendrocyte Senescence in Alzheimer’s Models
In preclinical models, microglia and astrocytes—the CNS’s primary immune and support cells—have been observed to adopt senescence-like profiles when exposed to Aβ accumulation. These senescent glial cells lose their ability to effectively clear debris while releasing inflammatory mediators that exacerbate neuronal stress. Astrocytic senescence has been particularly linked to reduced neurotrophic support and impaired metabolic balance. Likewise, oligodendrocyte progenitor cells (OPCs), which normally differentiate to maintain myelin integrity, can exhibit senescence when subjected to chronic exposure to Aβ or oxidative stress. This shift disrupts normal myelination and axonal stability, contributing to neural vulnerability.
Collectively, these findings suggest that senescence across multiple glial subtypes contributes to widespread cellular dysfunction observed in AD-related neurodegeneration.
Senescence-Associated Pathways and Neurodegenerative Progression
Mechanistic analyses have revealed that senescent neural and glial cells may promote both tau hyperphosphorylation and the spread of Aβ pathology. Elevated levels of p16^INK4a^ expression, a canonical marker of senescence, have been identified in experimental AD models prior to the formation of neurofibrillary tangles. This observation implies that senescence may precede or even initiate downstream degenerative processes. Additional studies indicate that tau accumulation itself may act as a pro-senescent trigger by disrupting cytoskeletal dynamics and mitochondrial function. Furthermore, the SASP can alter the extracellular matrix and vascular integrity, potentially linking cerebrovascular aging to neural degeneration.
Altogether, these mechanisms underscore the intertwined nature of cellular senescence and AD pathology within laboratory systems.
Investigating Senescent Cell Clearance in Experimental Research
Preclinical research has explored various methods for selectively removing senescent cells to study their biological role in neurodegeneration. Genetic or pharmacologic clearance of senescent astrocytes and microglia in transgenic models has been shown to decrease tau pathology and reduce neuroinflammatory markers. The resulting tissue-level changes correspond with improved cellular viability and synaptic density in experimental settings. These observations support the hypothesis that senescent cells actively exacerbate degenerative cascades rather than simply marking damaged tissue.
Beyond clearance, researchers are also investigating genetic regulators associated with senescence-linked stress responses, including ADAMTS4 and BIN1, both implicated in genotoxic stress and extracellular matrix modulation. Such findings provide additional context for understanding how age-related genomic and proteomic alterations contribute to AD-like pathology.
Conclusion
The convergence of evidence from diverse experimental systems suggests that cellular senescence represents more than a byproduct of aging—it may act as a mechanistic amplifier of neurodegenerative signaling. In vitro and in vivo studies consistently indicate that senescent glial and progenitor cells alter their microenvironment in ways that accelerate protein aggregation, inflammation, and neural decline.
Future research will be crucial in delineating whether senescence is a primary initiator or a secondary consequence of these processes. Continued exploration of molecular markers, regulatory pathways, and senescence-modulating compounds will advance understanding of how cellular aging interfaces with neurodegeneration, potentially informing new directions for basic and translational neuroscience.
References
- Bryant, A. G., Hu, M., Carlyle, B. C., Arnold, S. E., Frosch, M. P., Das, S., … & Bennett, R. E. (2020). Cerebrovascular senescence is associated with tau pathology in Alzheimer’s disease. Frontiers in Neurology, 11, 575953.
- Saez-Atienzar, S., & Masliah, E. (2020). Cellular senescence and Alzheimer disease: the egg and the chicken scenario. Nature Reviews Neuroscience, 21(8), 433-444.
- Guerrero, A., De Strooper, B., & Arancibia-Cárcamo, I. L. (2021). Cellular senescence at the crossroads of inflammation and Alzheimer’s disease. Trends in Neurosciences, 44(9), 714-727.
- Liu, R. M. (2022). Aging, cellular senescence, and Alzheimer’s disease. International Journal of Molecular Sciences, 23(4), 1989.
- Han, X., Zhang, T., Liu, H., Mi, Y., & Gou, X. (2020). Astrocyte senescence and Alzheimer’s disease: A review. Frontiers in Aging Neuroscience, 12, 148.
- Zhang, P., Kishimoto, Y., Grammatikakis, I., Gottimukkala, K., Cutler, R. G., Zhang, S., … & Mattson, M. P. (2019). Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nature Neuroscience, 22(5), 719-728.
- Maiese, K. (2023). The implications of telomere length: advanced aging, cell senescence, MRI phenotypes, stem cells and Alzheimer’s disease. Current Neurovascular Research, 20(2), 171-174.
- Martel, J., Ojcius, D. M., Wu, C. Y., Peng, H. H., Voisin, L., Perfettini, J. L., … & Young, J. D. (2020). Emerging use of senolytics and senomorphics against aging and chronic diseases. Medicinal Research Reviews, 40(6), 2114-2131.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
